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Abstract
Aim: Altered adipokine serum concentrations early reflect impaired adipose tissue function in obese patients with type 2
diabetes (T2D). It is not entirely clear whether these adipokine alterations are already present in prediabetic states and so far
there is no comprehensive adipokine panel available. Therefore, the aim of this study was to assess distinct adipokine
profiles in patients with normal glucose tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or
T2D.
Methods: Based on 75 g oral glucose tolerance tests, 124 individuals were divided into groups of IFG (n=35), IGT (n=45), or
NGT (n=43). Furthermore, 56 subjects with T2D were included. Serum concentrations of adiponectin, chemerin, fetuin-A,
leptin, interleukin (IL)-6, retinol-binding protein 4 (RBP4), monocyte chemoattractant protein (MCP)-1, vaspin, progranulin,
and soluble leptin receptor (sOBR) were measured by ELISAs.
Results: Chemerin, progranulin, fetuin-A, and RBP4, IL-6, adiponectin and leptin serum concentrations were differentially
regulated among the four investigated groups but only circulating chemerin was significantly different in patients with IGT
compared to those with IFG. Compared to T2D the IFG subjects had higher serum chemerin, progranulin, fetuin-A and RBP4
levels which was not detectable in the comparison of the T2D and IGT group.
Conclusion: Alterations in adipokine serum concentrations are already detectable in prediabetic states, mainly for chemerin,
and may reflect adipose tissue dysfunction as an early pathogenetic event in T2D development. In addition, distinct
adipokine serum patterns in individuals with IFG and IGT suggest a specific role of adipose tissue in the pathogenesis of
these prediabetic states.
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Introduction
Adipose tissue dysfunction belongs to the primary defects in
o b e s i t ya n dm a yl i n ko b e s i t yt os e v e r a lh e a l t hp r o b l e m si n c l u d i n g
increased risk of type 2 diabetes, fatty liver, and cardiovascular
disease [1–6]. Altered adipokine serum concentrations are an
early symptom of impaired adipose tissue function and may
contribute to the development of obesity-associated disorders. In
patients with type 2 diabetes, elevated tumor necrosis factor a
(TNFa), C-reactive protein (CRP), interleukin (IL) -1, -6, -8,
plasminogen activator inhibitor-1 (PAI-1), retinol binding protein
4 (RBP4), chemerin, fetuin-A, visfatin/Nampt, resistin and
reduced adiponectin and IL-10 serum concentrations have been
reported [7–11], reviewed in [1,5]. However, it is not entirely
clear whether these alterations in adipokine serum concentrations
are already present in prediabetic states of isolated impaired
fasting glycemia (IFG), isolated impaired glucose tolerance (IGT),
or combined IFG/IGT. Furthermore, at present there is no
comprehensive comparison of adipokine pattern across all stages
of glucose intolerance starting from NGT status available. Here,
we sought to identify adipokines, which are either increased or
decreased in individuals with the prediabetic states IFG and IGT
compared to normal glucose tolerant (NGT) healthy controls and
subjects with type 2 diabetes. In addition, we tested the hypothesis
that isolated IFG and IGT are associated with distinct adipokine
patterns which reflect the pathophysiological differences between
IFG and IGT. Taking into account the dominant effect of obesity,
age and gender on adipokine levels we present all analyses
adjusted for these factors. Key defects in IFG include reduced
hepatic insulin sensitivity, beta cell dysfunction, and/or chronic
low beta cell mass, altered glucagon-like peptide-1 secretion, and
inappropriately elevated glucagon secretion. In contrast, IGT is
characterised by reduced peripheral insulin sensitivity, near-
normal hepatic insulin sensitivity, progressive loss of beta cell
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polypeptide, and inappropriately elevated glucagon secretion
[12,13]. In addition, the aetiologies of IFG and IGT seem to
differ, with IFG being predominantly related to genetic factors,
smoking, and male gender, while IGT is predominantly related to
physical inactivity, unhealthy diet, and short stature [13]. Our
aim is to elucidate distinct pathomechanisms for either IFG or
IGT by comparing adipokine serum patterns between these
prediabetic states and NGT and T2D. Furthermore, we aim to




A total of 864 Caucasian men (n=413) and women (n=451)
have been consecutively recruited in the context of a study on
insulin resistance at the Department of Medicine, University of
Leipzig, to represent a wide range of obesity, insulin sensitivity,
and glucose tolerance. On the basis of a 75-g oral glucose
tolerance test (OGTT) according to the criteria of the American
Diabetes Association [14], 179 individuals for whom complete
data sets for the described parameters were available, were
selected from this cohort and divided into groups of isolated IFG
(n=35), isolated IGT (n=445), NGT (n=453), T2D (n=56).
Individuals with NGT were defined by a fasting plasma glucose
,6.0 mmol/l and a 120-min plasma glucose ,7.8 mmol/l,
patients with isolated IGT by a fasting plasma glucose
,6.0 mmol/l and a 120-min plasma glucose .7.8 mmol/l and
,11.1 mmol/l. Isolated IFG was defined by a fasting plasma
glucose $6.1 mmol/l and #7.0 mmol/l as well as a 120-min
plasma glucose ,7.8 mmol/l following WHO criteria [15]. T2D
was defined by 120-min glucose $11.1 mmol/l. All individuals
fulfilled the following exclusion criteria: 1) Any acute or chronic
inflammatory disease as determined by a leucocyte count
.7000 Gpt/l, CRP .5.0 mg/dl, or clinical signs of infection; 2)
antibodies against glutamic acid decarboxylase (GAD); 3) history
of hypertension or systolic blood pressure (SBP) .140 mmHg and
diastolic blood pressure (DBP) .85 mmHg; 4) clinical evidence of
either cardiovascular or peripheral artery disease; 5) thyroid
dysfunction; 6) alcohol or drug abuse; 7) pregnancy. All study
protocols have been approved by the ethics committee of the
University of Leipzig. All participants gave written informed
consent before taking part in the study.
Measurement of body fat content, glucose metabolism,
and insulin sensitivity
Percentage body fat was measured by dual X-ray absorptiom-
etry (DEXA). The OGTT was performed after an overnight fast
with 75-g standardized glucose solution (Glucodex Solution 75 g;
Merieux, Montreal, Canada). All baseline blood samples were
collected between 8:00 and 10:00 am after an overnight fast.
Plasma insulin was measured with an enzyme immunometric assay
for the IMMULITE automated analyzer (Diagnostic Products,
Los Angeles, CA). Serum high-sensitive CRP, and IL-6 were
measured as previously described [16].
Insulin sensitivity was assessed using the HOMA-IR as dscribed
[17] and in a subgroup (n=51) with the euglycemic-hyperinsu-
linemic clamp method using a previously described protocol [18].
Glucose infusion rate (GIR) was calculated from the last 45 min of
the clamp, in which glucose infusion rate could be kept constant in
order to achieve the target plasma glucose concentration of 5.5
(65%) mmol/L.
Measurement of adipokine serum concentrations
All baseline blood samples were collected between 8:00 and
10:00 am after an overnight fast. Serum concentrations of all
adipokines have been measured in triplicate and 10 replicates per
ELISA plate have been used as internal quality controls. Serum
adiponectin was measured using an ELISA (AdipoGen; Seoul,
Korea; reference range: 8.1–19.5 mg/ml inter-assay variability:
5.1%; intra-assay variability: 4.4%). Serum leptin was measured
using an ELISA (Mediagnost, Reutlingen, Germany; sensitivity:
0.2 ng/ml; reference range of normal leptin values at a BMI of
25 kg/m
2: males: 1.2–8.9 ng/ml, females: 8–24 ng/ml; inter- and
intra-assay variability: ,7%). Serum RBP4 was measured by
ELISA (AdipoGen; Seoul, Korea;). Percent coefficient of variation
for intra- and inter-assay replicate samples was less than 9% for
RBP4. Serum MCP-1 concentrations were measured by an
immunoassay system (Quantikine human MCP-1 Immunoassay;
R&D Systems, Minneapolis, MN) (inter assay variability: ,10%;
intra-assay variability: ,8%). Serum vaspin was measured using a
previously desribed ELISA [19] (inter-assay variability: 8.7%;
intra-assay variability: ,5%). Serum progranulin was measured
using a previously developed ELISA [20] (inter-assay variability:
8.5%; intra-assay variability: 6.9%). Serum soluble leptin receptor
(sOBR) was measured as previously described [21] (inter- and
intra-assay variability: ,11.7%). Serum chemerin was measured
by ELISA (Biovendor, Heidelberg, Germany) (inter-assay vari-
ability: ,10%; intra-assay variability: 5.1%). Serum fetuin-A was
measured by ELISA (Biovendor, Heidelberg, Germany) (inter-
and intra-assay variability: ,8%).
Statistical analyses
Data are shown as means 6 SD unless stated otherwise. Before
statistical analysis, non-normally distributed parameters were
logarithmically transformed to approximate a normal distribution.
Overall group differences were assessed by ANOVA with and
without adjustment for age, gender, and body mass index (BMI).
In order to adjust for age, gender, BMI a general linear model
analysis was performed for each adipokine. Non-standardizes
residuals were then taken forward as a new dependent variable in
the ANOVA analysis for all four groups (NGT, IFG, IGT, T2D).
For p-values ,0.05 in the ANOVA adjusted for these co-variates a
Tukey-HSD posthoc test was performed. Statistical analysis was
performed using SPSS version 15.0 (Chicago, IL). Additionally, we
performed a second analog analysis but adjusted with waist-to-hip-
ratio (WHR) and waist circumference instead of BMI to assess
possible effects of fat distribution.
Power calculation
Based on the distribution of the parameters in our study, we
would be able to detect a mean difference of 620% in serum
adipokine levels with a power of 17% to 100% (vaspin 17%, leptin
21%, IL-6 28%, adiponectin 35%, RBP4 46%, MCP-1 99%,
chemerin 99%, progranulin 100%, fetuin-A 100%) at a signifi-
cance level of 0.05 with a sample size of at least 35 subjects per
group.
Results
A total of 179 men (n=74) and women (n=105) with an age
range from 18 to 77 years and BMI from 21 to 62 kg/m
2 were
studied in groups of NGT, IFG, IGT and T2D (table 1). While age
distribution was comparable BMI, waist-to-hip-ratio (WHR), waist
circumference, HbA1c, hsCRP and parameters of insulinsensitiv-
ity (HOMA-IR and whole body glucose uptake) was significantly
different in the comparison of all four groups (table 1). Gender
Adipokines in IFG and IGT
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adiponectin and leptin (data not shown). BMI had significant
impact on progranulin, RBP4, adiponectin and leptin levels (table
S1). Moreover, progranulin, fetuin-A, RBP4, IL-6 and leptin were
significantly correlated increased waist circumference and adipo-
nectin with decreased waist circumference (table 2). In contrast,
chemerin was not correlated to waist or hip circumference but
hsCRP (p,0.001, r=0.262) and HbA1c (p,0.001, r=0.294,
table 2). Chemerin, progranulin, fetuin-A, RBP4, IL-6, leptin and
adiponectin serum concentrations significantly correlated with
HOMA-IR (independent from BMI, age and gender effects).
Whereas higher HOMA-IR was associated with elevated concen-
tration of chemerin (p=0.022; beta=0.009), progranulin
(p,0.001; beta=0.016), fetuin-A (p,0.001; beta=0.012), RBP4
(p,0.001; beta=0.049), IL-6 (p=0.012; beta=0.049) and leptin
(p,0.001; beta=0.031) it was negatively correlated with adipo-
nectin serum levels (p=0.002; beta=20.028). In the subgroup of
non-diabetic subjects the effects remained significant for progra-
nulin, fetuin-A, RBP4, adiponectin and showed a trend with a
consistent effect direction for leptin (table S1).
Consistently with published data there were significant
differences in the overall comparison of all four groups in the
serum levels detectable for progranulin, fetuin-A, RBP4, IL-6,
adiponectin and leptin. All differences remained significant after
adjusting for age, gender and BMI. In contrast, MCP-1, vaspin
and sOBR did not show significantly altered serum levels between
NGT, IFG, IGT or T2D (table 3). Compared to NGT controls,
adiponectin serum concentrations were significantly lower in
individuals with IGT (p=0.008). Patients with IGT had
significantly higher progranulin (p,0.004), RBP4 (p=0.010),
Table 1. Characteristics of the study population.
NGT IFG IGT T2D p-value
(ANOVA)
mean (+-SD) mean (+-SD) mean (+-SD) mean (+-SD)
[range] [range] [range] [range]
N (m/f) 43 (20/23) 35 (13/22) 45 (17/28) 56 (24/32)
Age 61.3 (69.3) 61.9 (612.3) 63.3 (68.8) 62.4 (67.2) 0.78
[44–76] [20–80] [40–77] [45–78]
BMI (kg/m2) 29.6 (66.3) 33.4 (67.6) 35.2 (68.2) 33.9 (64.1) 0.001
[21.3–52.7] [23.4–55.5] [25.1–62.0] [26.8–46.5]
Body fat (%) 26.1 (68.1) 31.2 (69.6) 34.5 (69.5) 30.0 (64.1) ,0.001
[12.5–49.8) [16.2–52.7] [22.2–59.8] [22.9–42.1]
fasting glucose (mmol/l) 5.01 (60.45) 7.11 (60.69) 5.60 (60.37) 6.56 (60.91) ,0.001
[3.59–5.85) [6.25–8.61] [4.52–6.03] [5.24–9.39]
2-hr glucose (mmol/l) 5.97 (60.75) 5.83 (60.60) 8.9 (60.83) NA ,0.001
[4.65–7.32] [4.44–7.21] [7.84–10.94] NA
HbA1c (%) 5.42 (60.23) 5.59 (60.26) 5.92 (60.19) 6.4 (60.36) ,0.001
[5.1–6.1] [5.3–6.5] [5.6–6.3] [5.8–7.4]
fasting insulin (pmol/l) 62.9 (663.9) 87.6 (663.0) 152 (6103) 197.1 (697.5) ,0.001
[6–351] [17–347] [25–411] [71–504]
hsCRP (mg/dl) 0.52 (60.81) 0.53 (60.81) 0.85 (60.73) 1.19 (60.78) ,0.001
[0.01–4.31] [0.02–4.19] [0.05–3.17] [0.13–3.64]
Free fatty acids (mmol/l) 0.34 (60.21) 0.60 (60.34) 0.63 (60.28) 0.91 (60.31) ,0.001
[0.05–0.94] [0.18–1.98] [0.13–1.34] [0.19–1.43]
Waist circumference (cm) 95.2 (618.2) 106.0 (619.9) 112.3 (616.8) 114.4 (613.6) ,0.001
[58–135] [65–150] [75–156] [65–144]
Hip circumference (cm) 107.5 (618.3) 115.9 (619.4) 116.6 (618.6) 114.6 (610.5) 0.046
[81–184] [88–193] [96–177] [94–135]
WHR 0.89 (60.13) 0.92 (60.13) 0.97 (60.14) 1.0 (60.13) ,0.001
[0.64–1.16] [0.64–1.26] [0.69–1.26] [0.69–1.34]
HOMA_IR 2.1 (62.2) 4.0 (62.9) 5.45 (63.70) 8.26 (64.3) ,0.001
[0.2–11.9] [0.7–16] [1.0–14.9] [3.1–26.2]
whole body glucose uptake 86.5 (626.2) 63.3 (634.7) 75.7 (636.4) 29.7 (618.9) ,0.001
(mmol/kg/min), [23–119] [9–98] [10–119] [8–62]
(N=22) (N=7) (N=12) (N=10)
Group specific arithmetic means, standard deviation and ranges are provided. Furthermore, p-values for the univariate ANOVA are given to assess significant differences
between the groups.
doi:10.1371/journal.pone.0013911.t001
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the NGT group. As a key result of our study, we found distinct
adipokine patterns in individuals with isolated IFG and isolated
IGT independent from BMI. Individuals with IGT and T2D had
significantly higher chemerin, progranulin, fetuin-A, and RBP4
serum concentrations than IFG and NGT subjects (table 3).
However, only differences in circulating chemerin between the
IFG and IGT group remained significant after adjusting for age,
Table 2. Univariate correlation of adipokine concentrations with anthropometric parameters, CRP levels and HbA1c.
waist [cm] hip [cm] body fat [%] hsCRP [mg/dl] HbA1c [%]
Adipokine p-value r p-value r p-value r p-value r p-value r
Chemerin [ng/ml] 0.293 0.079 0.187 0.099 0.294 0.079 ,0.001 0.262 ,0.001 0.294
Progranulin [ng/ml] ,0.001 0.400 ,0.001 0.263 ,0.001 0.316 ,0.001 0.488 ,0.001 0.387
Fetuin-A [mg/ml] ,0.001 0.268 ,0.001 0.266 0.003 0.219 0.005 0.210 ,0.001 0.348
RBP4 [mg/ml] ,0.001 0.394 ,0.001 0.299 ,0.001 0.350 ,0.001 0.374 ,0.001 0.391
IL-6 [pg/ml] 0.002 0.230 0.057 0.143 0.017 0.179 ,0.001 0.319 ,0.001 0.309
Adiponectin [mg/ml] ,0.001 20.476 0.072 20.135 0.090 20.127 0.026 20.166 ,0.001 20.293
sOBR [ng/ml] 0.379 20.066 0.866 0.011 0.822 20.017 0.081 0.131 0.277 0.082
Vaspin [ng/ml] 0.928 20.007 0.666 0.033 0.217 0.093 0.570 0.043 0.425 0.060
Leptin [ng/ml] ,0.001 0.355 ,0.001 0.732 ,0.001 0.675 ,0.001 0.410 0.031 0.162
MCP-1 [pg/ml] 0.408 0.062 0.396 20.064 0.630 20.036 0.174 20.102 0.220 0.092
Data present p-values and Pearson correlation coefficients assessed by univariate correlation analysis in all 179 subjects. P-values ,0.05 were considered as nominal
significant and marked in bold italic.
doi:10.1371/journal.pone.0013911.t002
Table 3. Adipokine serum concentrations in individuals with normal glucose tolerance (NGT), isolated impaired fasting glucose























Chemerin (ng/ml) 197.4 (638.7) 193.3 (636.9) 227.3 (642.5) 237.9 (650.2) ,0.001 ,0.001 0.828 0.016 0.002 ,0.001 ,0.001 0.567
[113–323] [131–324] [166.7–366.9] [155.2–380.2]
Progranulin (ng/ml) 138.8 (624.9) 155.4 (631.3) 178.2 (640.0) 192.2 (653.7) ,0.001 ,0.001 0.693 0.004 0.140 ,0.001 ,0.001 0.227
[98–205] [106–239] [95–257] [104–319]
Fetuin-A (mg/ml) 275.4 (643.5) 299.8 (646.2) 324.2 (651.5) 334.6 (650.8) ,0.001 ,0.001 0.305 0.001 0.249 ,0.001 0.011 0.574
[210–399] [217–419] [214–398] [205–421]
RBP4 (mg/ml) 49.2 (622.1) 62.9 (628.4) 70.8 (623.6) 78.2 (624.1) ,0.001 ,0.001 0.279 0.010 0.635 ,0.001 0.007 0.135
[13.6–106.7] [23.4–152.1] [26.6–112.4] [42.6–143.8]
IL-6 (pg/ml) 2.15 (61.31) 2.88 (62.73) 2.68 (64.16) 5.0 (62.87) ,0.001 ,0.001 0.963 0.096 0.317 ,0.001 ,0.001 ,0.001
[0.3–5.9] [0.1–11.5] [0.04–27.0] [1.7–17.3]
Adiponektin (mg/ml) 8.8 (64.7) 7.2 (64.7) 6.2 (63.2) 5.8 (62.8) 0.002 0.001 0.088 0.008 0.908 0.001 0.603 0.930
[2.6–23.7] [1.9–23.2] [1.3–13.3] [1.4–10.9]
Leptin (ng/ml) 16.6 (612.0) 21.9 (616.9) 22.3(616.4) 25.3 (610.7) 0.001 ,0.001 0.994 0.802 0.935 ,0.001 ,0.001 ,0.001
[3.0–61.3] [3.5–71.9] [3.2–72.9] [8.4–53.4]
sOBR (ng/ml) 27.3 (67.1) 28.7 (69.9) 27.8 (66.2) 29.6 (67.5) 0.441
[15.0–44.6] [15.0–62.3] [15.6–43.7] [15.6–55.9]
Vaspin (ng/ml) 1.55 (61.31) 2.01 (61.77) 1.89 (61.76) 2.07 (61.45) 0.179
[0.1–5.2] [0.1–6.8] [,0.1–7.8] [0.1–6.8]
MCP-1 (pg/ml) 398.5 (678.4) 384.6 (673.2) 398.5 (698.4) 405.2 (6106.6) 0.912
[237–561] [259–526] [246–624] [206–657]
Data present means 6 SD. P-values in the adjusted ANOVA are corrected for age, gender and BMI. Tukey-HSD post-hoc test was performed only when the unadjusted
ANOVA showed significant differences.
doi:10.1371/journal.pone.0013911.t003
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differences in adiponectin, leptin, sOBR, vaspin, MCP-1, and IL-6
serum concentrations between the IGT and IFG groups.
However, the post hoc test including all groups revealed that the
adipokine serum profile in IFG subjects showed more similarities
with the NGT group and IGT subjects overlap in a greater extend
with the T2D group (table 3). There were no significant differences
detectable between the NGT and IFG group after adjusting for
age, sex and BMI and only circulating IL-6 and leptin varied
between T2D and IGT subjects (table 3).
When adjusting for waist circumference instead of BMI or
WHR out of all comparisons between the groups only one result
switched from non significant to nominal significant (difference of
IGF group to IGT group for progranulin levels, see table S2).
There were no substantial differences between adjustment with
BMI compared to WHR or waist circumference for comparisons
between NGT and IFG as well as NGT and IGT subjects. The
results for comparisons of NGT subjects to the T2D group
remained unaltered by adjustement with WHR or waist
circumference instead of BMI for all adipokines apart from leptin.
The significant difference in serum leptin concentrations dimin-
ished by adjustment with waist circumference (table S2).
Furthermore, the differences in serum leptin between the IGT
and T2D group were decreased after adjustment with WHR and
waist circumference instead of BMI (table S2).
Discussion
It has been recognized that altered circulating adipokine
patterns can be early abnormalities in obesity and may contribute
to obesity-related diseases including impaired glucose metabolism
and development of type 2 diabetes [22]. This study provides new
insight into adipokine-related pathomechanisms for the develop-
ment of prediabetic states including isolated IFG and isolated
IGT. It has been suggested that distinct pathomechanisms underly
the IFG and IGT phenotypes [13]. Hepatic insulin resistance,
stationary beta cell dysfunction, chronic low beta cell mass, and
others are causative factors in the pathogenesis of IFG, whereas
IGT is characterized by reduced peripheral insulin sensitivity,
near-normal hepatic insulin sensitivity, and progressive loss of beta
cell function [13]. However, the role of adipose tissue dysfunction
and altered adipokine serum concentrations in these different
entities of prediabetic states is not well defined.
Firstly, we confirmed previous reports (reviewed in [22]) that
prediabetic states (IFG, IGT or both) are associated with increased
progranulin, chemerin, fetuin-A, RBP4, and decreased adiponec-
tin serum concentrations compared to individuals with NGT. The
distinct adipokine serum patterns which we observed in individuals
with IFG and IGT suggest a specific role of adipose tissue in the
pathogenesis of these prediabetic states. Among nine different
adipokines, circulating chemerin, progranulin, fetuin-A, and RBP4
serum concentrations were significantly higher in individuals with
IGT compared to those with IFG. Increased circulating
concentrations of chemerin [23], progranulin [20], RBP4 [8],
and fetuin-A [24] have been shown to be associated with insulin
resistance. Therefore, our results support the view that peripheral
insulin resistance may represent a distinct pathology in IGT but
not in IFG development. However, only higher chemerin serum
concentrations were significantly associated with IGT after
adjustment for age, gender, and BMI. This suggests that elevated
RBP4 and fetuin-A serum levels do not represent an independent
mechanism linking adipose tissue dysfunction to impaired glucose
metabolism, whereas chemerin may be closely reflect causation in
obesity-related glucose intolerance. However, we can not entirely
exclude the possibility that statistical power was not sufficient to
detect age, gender, and BMI-independent differences in fetuin-A,
progranulin and RBP4 serum concentrations between the IGT
and IFG groups. It has been previously shown that fasting glucose
regulation is more related to abdominal obesity (waist circumfer-
ence), whereas 2 h glucose regulation is more associated with
overall degree of obesity [25,26]. Among the different adipokines,
only chemerin and progranulin serum concentration significantly
(and independently) predicted the difference between IFG and
IGT, suggesting that chemerin may be an additional predictor of
abdominal obesity in prediabetic state. We tested whether
adjusting for waist circumference or WHR would have a
significant effect on the observed significant group differences in
adipokine serum concentrations. Interestingly, adjusting for waist
circumference instead of BMI or WHR only affected the
difference in circulating progranulin between IFG and IGT
group. Since progranulin serum concentrations are both related to
visceral and whole body fat mass [20], this parameter could not be
used to dissect a pathophysiology of glucose metabolism in the
fasted versus postprandial state. In addition, significant group
difference in serum leptin concentrations were abolished by
adjustment for waist circumference. There were no additional
substantial differences between adjustment for BMI, waist
circumference or WHR for a better prediction of the glucose
tolerance category.
We recently reported that elevated progranulin serum concen-
trations were associated with visceral obesity, elevated plasma
glucose, and dyslipidemia [20]. We identified progranulin as a
novel marker of chronic inflammation in obesity and type 2
diabetes which closely reflects omental adipose tissue macrophage
infiltration [20]. Therefore, elevated progranulin serum concen-
trations in IGT compared to IFG patients may suggest that
inflammation of adipose tissue contributes to the development of
IGT but not of IFG. Further studies are necessary to elucidate
such potential differences in adipose tissue morphology between
individuals with IGT and IFG.
Chemerin is highly expressed in liver and adipose tissue and is
involved in anti-inflammatory pathways in activated macrophages
[23]. Chemerin is known to be associated with a range of markers
of the metabolic syndrome [27]. Recently, chemerin was shown to
be increased by hyperinsulinaemia in women with PCOS [28].
Moreover, changes in HOMA-IR under metformin treatment
significantly predict changes in serum chemerin [28]. Our results
support these findings since significantly higher circulating
chemerin in individuals with IGT was associated with significantly
higher fasting insulin serum concentrations in patients with IGT
compared to those with IFG.
Since false negative associations due to the limited sample size
should be taken into account especially for vaspin, leptin, IL-6,
adiponectin and RBP4 further studies with extended sample size
are required to elucidate the relative role of the different
adipokines in relation to deterioration of glucose metabolism from
IFG to IGT and ultimately T2D.
In conclusion, alterations in adipokine serum concentrations are
already detectable in prediabetic states and may reflect adipose tissue
dysfunction as an early pathogenic event in type 2 diabetes
development. In addition, higher chemerin and progranulin serum
concentrations in the IGT compared to the IFG group suggest a
specific roleof adiposetissue in the pathogenesis of IGT, but not IFG.
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